Dydrogesterone Estrogen/progestogen Receptor agonist

Cat.No.S4097

Dydrogesterone (NSC 92336) is an orally active progestogen which acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus.
Dydrogesterone Estrogen/progestogen Receptor agonist Chemical Structure

Chemical Structure

Molecular Weight: 312.45

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 312.45 Formula

C21H28O2

Storage (From the date of receipt)
CAS No. 152-62-5 Download SDF Storage of Stock Solutions

Synonyms NSC 92336 Smiles CC(=O)C1CCC2C1(CCC3C2C=CC4=CC(=O)CCC34C)C

Solubility

In vitro
Batch:

DMSO : 62 mg/mL (198.43 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 62 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
progestogen Receptor [1]
In vitro
Dydrogesterone alone or in combination with estrogen to endothelial cells results in neutral effects on NO synthesis and on the activity and expression of eNOS. [1]
In vivo
Dydrogesterone abrogates stress-triggered increase of the abortion rate in mice. This compound restores the percentage of CD8+ uterus cells back to levels seen in control mice. It significantly lowers the relative number of TNF-α-producing uterine cells on days 7.5, 9.5, and even on 10.5 in mice. This chemical results in significantly higher percentages of pregnancy protective IL-4+ uterus cells beginning on gestation day 7.5 and, even more strikingly, maintained until day 10.5 in stressed mice. [2] It abrogates the highly elevated abortion rate of the abortion rate in mice exposured to sound stress. This compound increases levels of plasma PIBF in stressed mice, but does not affect progesterone levels. It dramatically increases the percentage of IL-4 positive decidual immune cells in stressed mice. [3]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05186779 Terminated
Early Pregnancy Bleeding|Recurrent Pregnancy Loss
Center for Epidemiology and Health Research Germany|Abbott Products Operations AG
December 15 2021 --
NCT04287205 Completed
Endometriosis|Sexual Dysfunction
Kanuni Sultan Suleyman Training and Research Hospital
April 20 2019 Not Applicable
NCT02706470 Unknown status
Miscarriage Recurrent
Fudan University
May 2016 Phase 2|Phase 3
NCT01711216 Completed
Irregular Menstrual Cycle
Abbott
August 2012 --

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map